[1]李娜,李宝新,张云良,等.不同类型糖尿病视网膜病变患者血清和肽素和几丁质酶1水平的变化及影响因素[J].眼科新进展,2019,39(11):1044-1047.[doi:10.13389/j.cnki.rao.2019.0239]
　LI Na,LI Bao-Xin,ZHANG Yun-Liang,et al.Changes in serum copeptin and chitotriosidase levels in patients with different types of diabetic retinopathy and its factors[J].Recent Advances in Ophthalmology,2019,39(11):1044-1047.[doi:10.13389/j.cnki.rao.2019.0239]
点击复制

不同类型糖尿病视网膜病变患者血清和肽素和几丁质酶1水平的变化及影响因素/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年11期
页码:
1044-1047
栏目:
应用研究
出版日期:
2019-11-05

文章信息/Info

Title:
Changes in serum copeptin and chitotriosidase levels in patients with different types of diabetic retinopathy and its factors
作者:
李娜; 李宝新; 张云良; 张玛丽; 李杰; 田茜; 刘莉芳; 王翯; 郭淑芹
067000　河北省承德市，承德医学院（李娜，田茜）；071000　河北省保定市，保定市第一中心医院内分泌科（李宝新，张云良，张玛丽，李杰，刘莉芳，王翯，郭淑芹）
Author(s):
LI Na; LI Bao-Xin; ZHANG Yun-Liang; ZHANG Ma-Li; LI Jie; TIAN Xi; LIU Li-Fang; WANG He; GUO Shu-Qin
Chengde Medical College（LI Na，TIAN Xi），Chengde 067000，Hebei Province，China；Department of Endocrinology，the First Central Hospital of Baoding （LI Bao-Xin，ZHANG Yun-Liang，ZHANG Ma-Li，LI Jie，LIU Li-Fang，WANG He，GUO Shu-Qin），Baoding 071000，Hebei Province，China
关键词:
和肽素; 几丁质酶1; 糖尿病视网膜病变; 影响因素
Keywords:
copeptin; chitotriosidase; diabetic retinopathy; influencing factors
分类号:
R774
DOI:
10.13389/j.cnki.rao.2019.0239
文献标志码:
A
摘要:
目的　探讨不同类型糖尿病视网膜病变（diabetic retinopathy，DR）患者血清和肽素和几丁质酶1（Chitotriosidase，CHIT1）水平的变化，并分析其影响因素。方法　选取2型糖尿病患者197例作为研究对象，将患者分为：无糖尿病视网膜病变（non-diabetic retinopathy，NDR）组、非增生型糖尿病视网膜病变（non-proliferative diabetic retinopathy，NPDR）组、增生型糖尿病视网膜病变（proliferative diabetic retinopathy，PDR）组；另选取同期在我院进行体检的健康体检者60人作为正常对照（normal control，NC）组。收集所有受试者的一般资料，抽取受试者晨起空腹静脉血5 mL，检测总胆固醇、甘油三酯、谷草转氨酶、谷丙转氨酶、血肌酐及空腹血糖（fasting plasma glucose，FPG）、糖化血红蛋白（hemoglobin Alc，HbA1c）、空腹胰岛素（fasting plasma insulin，FINS）水平，用稳态模型评估法计算胰岛素抵抗指数（homeostasis model assessment for insulin resistance，HOMA-IR），计算肾小球滤过率。采用ELISA法测定血清和肽素和CHIT1含量。结果　NDR组、NPDR组、PDR组患者血清的和肽素、CHIT1含量均高于NC组，且随着DR病情进展逐渐升高，差异均有统计学意义（均为P＜0.05）；与NC组相比，NDR组、NPDR组、PDR组患者的FPG、HbA1c、HOMA-IR水平均依次升高，PDR组最高，差异均有统计学意义（均为P＜0.05）；各组受试者的总胆固醇、甘油三酯、谷草转氨酶、谷丙转氨酶、血肌酐、肾小球滤过率、FINS水平组间比较，差异均无统计学意义（均为P＞0.05）。Pearson相关性分析结果显示：血清和肽素含量与年龄、DM病程、SBP、FPG、HbA1c、HOMA-IR、CHIT1含量均呈正相关（r分别为0.11、0.75、0.52、0.83、0.88、0.58、0.96，均为P＜0.05）；血清CHIT1含量与年龄、DM病程、SBP、DBP、FPG、HbA1c、FINS、HOMA-IR、和肽素含量呈正相关（r分别为0.12、0.77、0.48、0.12、0.84、0.88、0.14、0.61、0.96，均为P＜0.05）。多元线性逐步回归分析结果显示：HbA1c、SBP、FPG是血清和肽素含量的独立影响因素，HbA1c、FPG、DM病程、HOMA-IR是血清CHIT1含量的独立影响因素。结论　DR患者的和肽素和CHIT1水平显著升高，且与DR的程度相关，二者可能共同参与了DR的发生发展。
Abstract:
Objective　To investigate the changes in serum copeptin and chitintriosidase (CHIT1) levels in patients with different types of diabetic retinopathy (DR) and its factors.Methods　Totally 197 patients with type 2 diabetes mellitus were enrolled in the study,then the patients were divided into non-diabetic retinopathy (NDR) group,non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy ( PDR) group;meanwhile another 60 healthy subjects who underwent physical examination in our hospital as the normal control (NC) group.Furthermore,clinical data of all subjects were collected.After 8 h-10 h of overnight fasting,5 mL venous blood samples were collected for measuring the total cholesterol,triglyceride,aspartate aminotransferase,alanine aminotransferase,serum creatinine,fasting plasma glucose (FPG),hemoglobin Alc (HbA1c) and fasting plasma insulin (FINS),the insulin resistance index (HOMA-IR) was calculated by the homeostasis model assessment,and the glomerular filtration rate was calculated.In addition,plasma copeptin and CHIT1 levels were determined by ELISA.Results　The blood copeptin and CHIT1 concentrations of patients in NDR group,NPDR group and PDR group were increased gradually as DR progressed,all of which were higher than those in NC group,the difference was statistically significant (all P＜0.05).Moreover,compared with the NC group,the FPG,HbA1c,and HOMA-IR levels of the NDR group,NPDR group and PDR group elevated in turn,simultaneously the highest was the PDR group,the difference was statistically significant (all P<0.05).There were no significant differences in the total cholesterol,triglyceride,aspartate aminotransferase,alanine aminotransferase,serum creatinine,glomerular filtration rate,and FINS levels between the groups (all P>0.05).Pearson correlation analysis showed that serum copeptin levels were positively correlated with age,diabetes duration,systolic blood pressure,FPG,HbA1c,HOMA-IR,CHIT1（r=0.11,0.75,0.52,0.83,0.88,0.58,0.96,all P＜0.05),and plasma CHIT1 levels were positively correlated with age,diabetes duration,systolic blood pressure,diastolic blood pressure,FPG,HbA1c,FINS,HOMA-IR,copeptin（r=0.12,0.77,0.48,0.12,0.84,0.88,0.14,0.61,0.96,all P＜0.05）.Further multiple regression analysis displayed that HbA1c,systolic blood pressure,FPG were independent influencing factors for serum copeptin levels.Meanwhile,HbA1c,FPG,diabetes duration and HOMA-IR were independent influencing factors for serum CHIT1 levels.Conclusion　It is found that the levels of copeptin and CHIT1 in patients with DR are significantly elevated and are related to the degree of DR,both which may be involved in the development of DR.

参考文献/References:

［1］　ZHANG G H，CHEN Y，CHEN W Q，ZHANG M Z.Prevalence and riskfactors for diabetic retinopathy in China：a multi-hospital-based cross-sectional study［J］.Br J Ophthalmol，2017，101（12）：1591-1595.
［2］　WANNAMETHEE S G，WELSH P，PAPACOSTA O，LENNON L，WHINCUP P H，SATTAR N.Copeptin，insulin resistance，and risk of incident diabetes in older men［J］.J Clin Endocrinol Metab，2015，100（9）：3332-3339.
［3］　LOPES M C，AMADEU T P，RIBEIRO-ALVES M，DA COSTA C H，RODRIGUES L S，BESSA E J C，et al.Identification of active sarcoidosis using chitotriosidase and angiotensin-converting enzyme［J］.Lung，2019，197（3）：295-302.
［4］　BJORNSTD P，MAAHS D M，JENSEN T，LANASPA M A，JOHNSON R J，REWERS M，et al.Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes［J］.J Diabetes Complications，2016，30（6）：1093-1096.
［5］　DI ROSA M，MALAGUARNERA L.Chitotriosidase：A new inflammatory marker in diabetic complications［J］.Pathobiology，2016，83：211-219.
［6］　LI B X，ZHANG Y L，ZHANG X，WANG H，MA S，GUO S Q，et al.Changes of serum leptin and neuropeptide Y in type 2 diabetes patients with hypertension of different grades and influencing factors［J］.Chin J Mod Med，2018，28（31）：851-855.
李宝新，张云良，张鑫，王翯，马爽，郭淑芹，等.2型糖尿病合并不同分级高血压患者血清瘦素和神经肽Y的变化及影响因素分析［J］.中国现代医学杂志，2018，28（31）：851-855.
［7］　WANG W Y，ZHANG X D.The role and research progress of NLRP3 inflammasome in diabetic retinopathy［J］.Rec Adv Ophthalmol，2018，38（6）：587-591.
王文颜，张学东.NLRP3炎症小体在糖尿病视网膜病变中的作用［J］.眼科新进展，2018，38（6）：587-591.
［8］　DIABETIC SOCIETY OF CHINESE MEDICAL ASSOCIATION.Chinese guidelines for the prevention and treatment of type 2 diabetes （2017 edition）［J］.Chin J Diabetes Mell，2018，10（1）：4-67.
中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）［J］.中华糖尿病杂志，2018，10（1）：4-67.
［9］　ZUO Z，JI X.Prognostic value of copeptin in patients with aneurysmal subarachnoid hemorrhage［J］.J Neuroimmunol，2019，330：116-122.
［10］　CHENG T Y，YAN G L，WANG D，KONG W J，ZHANG H R，SHA X，et al.Correlation between plasma level of copeptin and coronary atherosclerotic heart disease in diabetics［J］.J Southeast Univ（Med Ed），2016，35（3）：327-331.
程天宇，鄢高亮，王栋，孔文杰，张海荣，沙翔，等.和肽素水平与糖尿病患者合并冠心病的相关性研究［J］.东南大学学报（医学版），2016，35（3）：327-331.
［11］　LEE J H，CHAN Y H，LAI O F，PUTHUCHEARY J.Vasopressin and copeptin levels in children with sepsis and septic shock［J］.Intensive Care Med，2013，39（4）：747-753.
［12］　FENG G Y，HUANG W，REN H M.Diagnostic value of plasma and peptide levels in diabetic retinopathy［J］.Shandong Med J，2017，57（20）：76-78，Forward 2.
冯光勇，黄伟，任红苗.血浆和肽素水平对糖尿病视网膜病变的诊断价值［J］.山东医药，2017，57（20）：76-78，前插2.
［13］　ZHU F X，WU H L，TU K S，CHEN J X，ZHANG M，SHI C.Serum levels of copeptin are associated with type 2 diabetes and diabetic complications in Chinese population［J］.J Diabetes Complications，2016，30：1566-1570.
［14］　ZHAO Q，WU X X，ZHOU J，WANG X.Elevated plasma levels of copeptin linked to diabetic retinopathy in type 2 diabetes［J］.Mol Cell Endocrinol，2017，442：106-112.
［15］　EWA Z · URAWSKA-PLAKSEJ E，KRATZ E M，FERENS-SIECZKOWSKA M，KNAPIK-KORDECKA M，PIWORAR P.Changes in glycosylation of human blood plasma chitotriosidase in patients with type 2 diabetes［J］.Glycoconj J，2016，33（1）：29-39.
［16］　PEDRO-BOTET J.Serum chitotriosidase activity is increased in subjects with atherosclerosis disease［J］.Arterioscler Thromb Vasc Biol，2004，16（4）：171-172.
［17］　STEINACKER P，VERDR F，FANG L，FENEBERG E，OECKL P，ROEBER S，et al.Chitotriosidase （CHIT1） is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression［J］.J Neurol Neurosurg Psychiatry，2018，89（3）：239-247.
［18］　AYDOGDU A，TSCI I，TAPAN S，SONMEZ A，AYDOGAN U，AKBULIT H，et al.Women with polycystic ovary syndrome have increased plasmachitotriosidaseactivity：a pathophysiological link between inflammation and impaired insulin sensitivity［J］?Exp Clin Endocrinol Diabetes，2012，120（5）：261-265.
［19］　TURAN E，SOZMEN B，ELTUTANl M，SOZMEN E Y.Serum chitotriosidase enzyme activity is closely related to HbA1c levels and the complications in patients with diabetes mellitus type 2［J］.Diabetes Metab Syndr，2017，11（Suppl 1）：503-506.
［20］　SONMEZ A，HAYMANA C，TAPAN S，SAFER U，CELEBI G，OZTURK O，et al.Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus［J］.Endocrine，2010，37（3）：455-459.
［21］　ZHANG Y L，YIN Q，GUO S Q，MA Z P，XU N，MA J X.Relationship of serum retinol binding protein 4 and insulin resistanc in diabetes mellitus patients with retinopathy［J］.J Microcirc，2016，26（2）：56-59.
张云良，殷俏，郭淑芹，马朝朋，许娜，马竞轩.2型糖尿病患者视网膜病变与视黄醇结合蛋白4和胰岛素抵抗的相关性研究［J］.微循环学杂志，2016，26（2）：56-59.

相似文献/References:

[1]丁红萍,季晓燕,黄江,等.血清几丁质酶1、鸢尾素表达与不同类型糖尿病视网膜病变患者微血管损伤的相关性[J].眼科新进展,2021,41(7):664.[doi:10.13389/j.cnki.rao.2021.0137]
　DING Hongping,JI Xiaoyan,HUANG Jiang,et al.Correlation between the expression of serum chitotriosidase and Irisin and microvascular injury in patients with different types of diabetic retinopathy[J].Recent Advances in Ophthalmology,2021,41(11):664.[doi:10.13389/j.cnki.rao.2021.0137]

备注/Memo

备注/Memo:
国家自然科学基金青年基金项目（编号：81500644）；河北省医学适用跟踪项目（编号：GL201679）
更新日期/Last Update: 2019-11-18